Table 1.

Characteristics of Acamprosate Treatment in Six Youth with Autistic Disorder

Age (years)	Final dose (mg/day)	Duration (weeks)	Concomitant medications	CGI-I score	Adverse effects	Clinical noted treatment effects
9	999	10	Aripiprazole	1	None	Improved language understanding, increased verbalizations
12	1,332	28	Clonidine, risperidone	1	Reduced appetite	Increased use of social language, improved eye contact, improved social relatedness
6	999	20	DDAVP, Synthroid	2	Transient mild nausea	Increased social communication, improved eye contact
8	1,332	30	Atomoxetine, guanfacine, risperidone	2	None	Improved social use of language, improved attention, improved eye contact
10	666	14	None	2	None	Improved eye contact, verbalizations, and general social relatedness
11	999	20	Sertraline	4	Reduced appetite	No changes noted

DDAVP=desmopressin; CGI-I=Clinical Global Impressions-Improvement.